Core Insights - NorthStrive Biosciences, Inc. has filed ten new U.S. patent applications to expand its proprietary EL-22 and EL-32 technologies into animal health and agricultural markets, focusing on muscle growth and weight return in animals [1][2]. Group 1: Patent Applications Overview - The ten patent applications consist of five covering EL-22 and five covering EL-32, applicable across various farmed animal categories including livestock, aquaculture, and poultry [2]. - Two applications specifically address the use of EL-22 and EL-32 as non-feed additive supplements to promote muscle tissue growth and increase muscle weight return per animal [3]. Group 2: Environmental and Health Benefits - Additional applications aim to utilize EL-22 and EL-32 for reducing gaseous emissions in livestock, which could lower environmental impact and mitigate risks associated with ruminal tympany [4]. - In aquaculture, applications have been filed to promote muscle growth in aquatic species, potentially reducing the time to reach commercially viable sizes and lowering energy costs [5]. - Further aquaculture applications focus on emissions reduction to help mitigate eutrophic conditions [6]. Group 3: Poultry Applications - The final set of applications pertains to the use of EL-22 and EL-32 in poultry, aimed at enhancing muscle growth and improving muscle yield per bird within standard growth timelines [7]. Company Background - NorthStrive Biosciences Inc. is a biopharmaceutical company under PMGC Holdings Inc., concentrating on developing advanced aesthetic medicines, with its lead asset, EL-22, designed to address muscle preservation during weight loss treatments [8].

NEWPORT BEACH, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- NorthStrive Biosciences Inc. (“NorthStrive”), a wholly owned subsidiary of PMGC Holdings Inc. (NASDAQ: ELAB) (the “Company,” “PMGC,” “we,” or “our”), today announced that it has executed a definitive, exclusive license agreement (“License Agreement”) with Modulant Biosciences LLC (“Modulant”), following the previously announced binding term sheet dated May 12, 2025. The License Agreement covers NorthStrive’s EL-22 and EL-32 assets and, pursuant to its ...

Core Insights - NorthStrive Biosciences, a subsidiary of PMGC Holdings, has provided an update on the timeline for Phase III of its AI Development Program in collaboration with Yuva Biosciences, with results expected in Q2 2026 [1][3] Group 1: Company Updates - NorthStrive Biosciences initiated Phase III of its AI Development Program on December 17, 2025, which is anticipated to last approximately 6 to 9 weeks [1] - Yuva Biosciences has developed improved sixth-generation classifier models that enhance screening accuracy and sensitivity, which will be utilized in the Phase III study [2] - The extended timeline for Phase III results is expected to yield more robust and reliable outcomes to support further development efforts [3] Group 2: Company Background - Yuva Biosciences specializes in mitochondrial sciences and employs advanced AI to identify therapeutic candidates targeting aging-related pathways, with its proprietary platform MitoNova™ [4] - NorthStrive Biosciences focuses on developing aesthetic medicines, with its lead asset EL-22 aimed at addressing obesity while preserving muscle during weight loss treatments [5] - PMGC Holdings is a diversified holding company that manages a portfolio through strategic acquisitions and investments across various industries [6]

Core Insights - PMGC Holdings Inc. has completed the acquisition of SVM Machining, Inc., marking its third CNC machine shop acquisition in California, which aligns with its strategy to build a multi-site machining platform for various industries [1][3]. Company Overview - PMGC Holdings Inc. is a diversified holding company focused on managing and growing its portfolio through strategic acquisitions and investments across multiple sectors [7]. - SVM Machining, Inc. is an ISO 9001:2015 certified precision CNC machining company that serves critical industries such as medical, aerospace, biotech, semiconductor, and transportation [2][6]. Financial Details - The acquisition was completed on a cash-free, debt-free basis, with a base purchase price of $2,250,000, which includes $2,000,000 paid at closing and a $250,000 indemnification holdback [5][9]. - For the fiscal year ending December 31, 2024, SVM reported revenue of $3,042,701 [4]. Strategic Implications - The acquisition enhances PMGC's footprint in precision manufacturing and supports its growth strategy in sectors like aerospace, defense, medical, and industrial [3][6]. - SVM's expertise in delivering high-quality, engineered solutions positions PMGC to better serve original equipment manufacturers and advanced technology customers [6].

Core Insights - The consumer staples sector has several oversold stocks that present potential buying opportunities for undervalued companies [1] Group 1: Oversold Stocks - Oddity Tech Ltd (NASDAQ: ODD) has an RSI of 25.3, with a stock price decline of approximately 20% over the past month, closing at $33.80 [3][6] - PMGC Holdings Inc (NASDAQ: ELAB) has an RSI of 16.2, with a significant stock price drop of around 73% over the past month, closing at $3.56 [4][6] - Zevia Pbc (NYSE: ZVIA) has an RSI of 26, with a stock price decrease of about 33% over the past month, closing at $1.68 [5][6] Group 2: Analyst Ratings and Price Targets - Keybanc analyst maintained an Overweight rating for Oddity Tech, lowering the price target from $70 to $50 [6] - Telsey Advisory Group analyst maintained an Outperform rating for Zevia, keeping the price target at $6 [6]

Core Viewpoint - Premarket trading is showing significant activity with notable price movements indicating potential investment opportunities before the market opens [1] Premarket Gainers - Ventyx Biosciences, Inc. (VTYX) increased by 57% to $15.79 [3] - Cardio Diagnostics Holdings, Inc. (CDIO) rose by 36% to $4.02 [3] - Monte Rosa Therapeutics, Inc. (GLUE) saw a 28% increase to $20.54 [3] - Momentus Inc. (MNTS) gained 27% reaching $12.50 [3] - BioAge Labs, Inc. (BIOA) went up by 13% to $17.50 [3] - Neumora Therapeutics, Inc. (NMRA) increased by 11% to $2.03 [3] - Mobileye Global Inc. (MBLY) rose by 10% to $13.45 [3] - Society Pass Incorporated (SOPA) increased by 10% to $3.47 [3] - SU Group Holdings Limited (SUGP) saw an 8% rise to $6.32 [3] - Critical Metals Corp. (CRML) gained 7% reaching $12.73 [3] Premarket Losers - Evolution Metals & Technologies Corp. (EMAT) decreased by 28% to $15.20 [4] - Ascent Solar Technologies, Inc. (ASTI) fell by 12% to $4.65 [4] - Apogee Enterprises, Inc. (APOG) saw a 10% decline to $33.30 [4] - Next Technology Holding Inc. (NXTT) dropped by 8% to $8.49 [4] - AST SpaceMobile, Inc. (ASTS) decreased by 7% to $90.45 [4] - Nomadar Corp. (NOMA) fell by 7% to $3.66 [4] - EZGO Technologies Ltd. (EZGO) decreased by 7% to $1.99 [4] - Cohen & Company Inc. (COHN) saw a 6% decline to $28.30 [4] - PMGC Holdings Inc. (ELAB) dropped by 4% to $5.34 [4] - Anghami Inc. (ANGH) decreased by 3% to $4.49 [4]

Core Viewpoint - PMGC Holdings Inc. (NASDAQ:ELAB) has executed a reverse stock split to consolidate shares and potentially attract a broader investor base, aiming to stabilize its stock price and enhance market perception [1][5]. Group 1: Reverse Stock Split Details - The reverse stock split consolidates every four shares of common stock into one, effective January 6, 2026 [1][5]. - Shareholders will receive one full share for each fractional portion, ensuring no loss in value [2][5]. - The stock's CUSIP number has been adjusted to 73017P409, while the trading symbol remains unchanged [2]. Group 2: Stock Performance and Market Capitalization - ELAB's current stock price is $1.61, reflecting a 13.38% increase with a $0.19 change [3]. - The stock has fluctuated between $1.38 and $1.6195 on the day of reporting, with significant volatility over the past year, peaking at $398.86 and dropping to $1.38 [3]. - The market capitalization of ELAB is approximately $683 million, with a trading volume of 741,689 shares on the NASDAQ exchange [4].

Industry Overview - The U.S. small and micro modular reactor (SMR/MMR) market is experiencing rapid growth due to energy security needs, data center demand, and federal support for advanced nuclear technologies [1][2] - The global SMR market, including MMRs, is projected to grow from approximately $7.5 billion in 2025 to over $16 billion by 2034, representing a compound annual growth rate (CAGR) of about 9% [3] Company Investment - PMGC Holdings Inc. has announced that its investment arm, PMGC Capital LLC, has acquired non-controlling shares in Nuclea Energy Inc., which focuses on the development of Micro Modular Reactor (MMR) and advanced nuclear energy solutions [1] - This investment aligns with PMGC Capital's strategic focus on supporting companies within long-term growth trends, including next-generation energy infrastructure and decarbonization [2] Nuclea Energy Inc. Profile - Nuclea Energy aims to provide clean, reliable, and economically competitive nuclear energy by replacing high-cost fossil fuels with micro nuclear technology [4] - The company is developing its Morpheus micro reactor for commercial readiness, targeting off-grid applications such as remote communities and military infrastructure [4] PMGC Capital LLC Profile - PMGC Capital is a multi-strategy investment firm focused on direct investments, strategic lending, and acquiring undervalued companies across diverse markets [5] - The firm's mission is to identify high-potential opportunities to deliver sustainable growth and maximize returns on capital [5] PMGC Holdings Inc. Profile - PMGC Holdings Inc. is a diversified holding company that manages its portfolio through strategic acquisitions and investments across various industries [6] - The company is committed to exploring opportunities in multiple sectors to maximize growth and value [6]

Core Viewpoint - PMGC Holdings Inc. will implement a 1-for-4 reverse stock split effective January 6, 2026, which will reduce the number of outstanding shares while proportionally adjusting the share price [1]. Group 1: Reverse Stock Split Details - The reverse stock split will consolidate every 4 shares of issued and outstanding common stock into one share, resulting in approximately 503,713 shares outstanding post-split, down from approximately 2,014,852 shares [3]. - The trading symbol for the common stock will remain "ELAB," but a new CUSIP number 73017P409 will be assigned [5]. - Outstanding stock awards, options, and shares reserved for the equity incentive plan will be adjusted proportionally to reflect the reverse stock split [5]. Group 2: Impact on Shareholders - Shareholders entitled to fractional shares will receive one full share for each fractional portion [5]. - The reverse stock split does not affect the overall value of shareholder equity; it only reduces the number of shares outstanding while adjusting the share price accordingly [5].

Core Insights - PMGC Holdings Inc.'s subsidiary, AGA Precision Systems LLC, has achieved AS9100 certification, enhancing its position in the aerospace, defense, and space manufacturing sectors [1][2]. Group 1: Certification Impact - The AS9100 certification is a globally recognized quality management standard that validates AGA's structured, process-based quality management system, which is crucial for operational excellence and product reliability [2]. - With this certification, AGA is expected to strengthen relationships with existing customers and support more complex, regulated programs, potentially leading to increased demand and recurring work [3]. Group 2: Company Overview - AGA Precision Systems LLC specializes in high-tolerance CNC machining, serving sectors such as aerospace, defense, and space, and is known for delivering precision components to stringent technical specifications [5]. - Founded over a decade ago, AGA has built a strong reputation based on quality and reliability, growing its business primarily through referrals and repeat orders without a formal sales or marketing strategy [6]. Group 3: Strategic Initiatives - The company is exploring the integration of humanoid robotics and advanced robotic automation systems into its manufacturing processes as part of a long-term strategy aimed at enhancing operational excellence and next-generation manufacturing capabilities [4].